USFDA issues zero observations for Gland Pharma Visakhapatnam API facility
Advertisement
Visakhapatnam: Gland Pharma has recently announced that the company has received zero observations from the US Food and Drug Administration (USFDA) after an inspection at the company's API Facility at JNPC, Visakhapatnam.
The inspection was conducted from 23rd January, 2023 to 27th January, 2023.
"We wish to inform you that the United States Food and Drug Administration (US FDA) conducted an inspection at the Company’s API Facility at JNPC, Visakhapatnam from 23rd January, 2023 to 27th January, 2023, and has been completed with Zero observations," Gland Pharma informed in a BSE filing.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.